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Craniosynostosis (CS) is a frequent congenital anomaly featuring
the premature fusion of 1 or more sutures of the cranial vault.
Syndromic cases, featuring additional congenital anomalies, make
up 15% of CS. While many genes underlying syndromic CS have
been identified, the cause of many syndromic cases remains
unknown. We performed exome sequencing of 12 syndromic CS
cases and their parents, in whom previous genetic evaluations were
unrevealing. Damaging de novo or transmitted loss of function
(LOF) mutations were found in 8 genes that are highly intolerant to
LOF mutation (P = 4.0 × 10−8); additionally, a rare damaging muta-
tion in SOX11, which has a lower level of intolerance, was identi-
fied. Four probands had rare damaging mutations (2 de novo) in
TFAP2B, a transcription factor that orchestrates neural crest cell mi-
gration and differentiation; this mutation burden is highly signifi-
cant (P= 8.2 × 10−12). Three probands had rare damagingmutations
in GLI2, SOX11, or GPC4, which function in the Hedgehog, BMP, and
Wnt signaling pathways; other genes in these pathways have pre-
viously been implicated in syndromic CS. Similarly, damaging de
novo mutations were identified in genes encoding the chromatin
modifier KAT6A, and CTNNA1, encoding catenin α-1. These findings
establish TFAP2B as a CS gene, have implications for assessing risk
to subsequent children in these families, and provide evidence im-
plicating other genes in syndromic CS. This high yield indicates the
value of performing exome sequencing of syndromic CS patients
when sequencing of known disease loci is unrevealing.
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Craniosynostosis (CS) is one of the most frequent birth de-fects, occurring once in every 2,000 live births. Affected
subjects typically require surgery early in life to allow normal
growth of the developing brain, which doubles in volume in the
first year. Syndromic CS cases, featuring additional extracranial
anomalies, make up ∼15% of cases. Rare Mendelian mutations
in more than 40 genes have been found to underlie syndromic
CS. These genes are highly clustered in several developmental
signaling cascades, including the BMP, Wnt, Ras/ERK, ephrin,
hedgehog, STAT, and retinoic acid pathways (1–3). Collectively,
the pleiotropic effects of syndromic mutations affect virtually all
organ systems, with the limbs and cardiovascular system most
commonly involved (1). Clinical manifestations are highly vari-
able among affected individuals even in syndromes caused by
recurrent mutations (e.g., Apert, Muenke, Pfeiffer syndromes),
demonstrating the variable expressivity of these mutations (1).
The diagnostic utility of screening for mutations or copy number
variants at known disease loci is quite high in syndromic CS, with
recent studies establishing a molecular diagnosis in >70% of cases
studied (4). Nonetheless, testing frequently remains unrevealing, de-
spite often striking clinical presentations. Given the high prevalence
of rare mutations with large effect in these syndromic cases, we
posited that mutation-negative syndromic probands would be an ex-
cellent source for identification of genes causing premature closure
of cranial sutures. We anticipated that disease-related mutations
in outbred families would likely be recognized as de novo or rare
transmitted damaging mutations in genes intolerant to loss of func-
tion (LOF) mutation (high probability of LOF intolerance [pLI])
and in pathways previously implicated in CS (see above) or other
congenital malformations (e.g., chromatin modification) (3, 5–7).
Significance
Craniosynostosis (CS) is a frequent congenital malformation
featuring premature fusion of cranial sutures; 15% of these
children have syndromic disease, often due to rare mutations
with large effect. While many genes causing Mendelian forms
of syndromic CS have been identified, clinical sequencing often
fails to identify a likely causative mutation. We performed
whole-exome sequencing of 12 case-parent trios with pre-
viously negative genetic evaluations. The results identified
likely pathogenic mutations in TFAP2B, KAT6A, GLI2, SOX11,
CTNNA1, and GPC4 in these families, adding several loci to
those known to cause syndromic CS. The findings have impli-
cations for determining risk of disease in subsequent offspring
and demonstrate that unexplained syndromic CS cases are a
particularly rich vein for discovery of CS loci.
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Results
Damaging De Novo Mutations in Syndromic CS. We ascertained 12
probands with syndromic CS, all of whom had undergone re-
constructive surgery for CS, who had negative genetic studies in
clinical laboratories. Prior evaluations included sequencing of
prevalent syndromic loci in all probands (SI Appendix, Table S1)
and assessment of copy number variants identified via array
comparative genomic hybridization in 9 probands. We also
searched for rare damaging mutations in SMAD6 implicated in
nonsyndromic CS (2) but found none in these kindreds. Clinical
features of these probands are described in SI Appendix, Table
S2. Exome sequencing was performed as previously described
(3), with 98.6% of all RefSeq coding bases and splice junctions
having 8 or more independent reads and median coverage of 42.
We identified de novo likely LOF and damaging missense mu-
tations (per metaanalytic support vector machine [MetaSVM])
as well as rare (minor allele frequency [MAF] < 2 × 10−5)
transmitted damaging heterozygous or hemizygous mutations.
We also identified recessive damaging genotypes with each
contributing allele having an allele frequency <10−3. Mutations
contributing to statistically significant results were confirmed by
Sanger sequencing of PCR products containing the variant site
amplified from genomic DNA; these variants are described in
Dataset S1.
Analysis of the distribution of de novo mutations showed that
there were 6 damaging de novo mutations among the 3,320 genes
that are highly intolerant to LOF mutations (pLI ≥ 0.9) (8),
significantly more than expected by chance (6.12-fold enrich-
ment, 1-tailed Poisson P = 5.4 × 10−4) (Table 1).
TFAP2B Mutations in Syndromic CS.We found 2 damaging de novo
mutations in TFAP2B: a canonical splice donor site mutation in
the third intron (IVS3 + 2T > A) and a missense mutation
p.K276R. Both mutations were absent in Exome Aggregation
Consortium (ExAC) (9). The probability of observing 2 damag-
ing de novo mutations in TFAP2B in a cohort of this size was
7.7 × 10−8 (Poisson test), well surpassing the threshold for
genome-wide significance (2.6 × 10−6). We also found 2 rare
transmitted LOF mutations in TFAP2B: a p.R382X premature
termination mutation and a p.M1I start loss mutation (Table 2).
These mutations are absent in >100,000 alleles in ExAC (9). The
probability of observing 2 damaging de novo (1 of these being
LOF) and 2 transmitted LOFs in this small cohort by chance was
highly unlikely (P = 8.2 × 10−12 by Poisson distribution and
binomial test, combined using Fisher’s method) (Methods).
Table 1. Enrichment of damaging de novo mutations in syndromic CS cases but not controls
Mutation class
Observed Expected
Enrichment P valueN Rate N Rate
Cases = 12, offspring studied = 13
All genes
Total 14 1.08 14.83 1.14 0.94 0.62
Syn 2 0.15 4.12 0.32 0.48 0.92
T-Mis 4 0.31 7.42 0.57 0.54 0.94
D-Mis 4 0.31 1.71 0.13 2.34 0.09
LOF 3 0.23 1.28 0.10 2.35 0.14
In-frame indels 1 0.08 0.30 0.02 3.36 0.26
Damaging 8 0.62 3.29 0.25 2.43 0.02
LOF-intolerant genes (pLI greater than or equal to 0.9)
Total 6 0.46 3.99 0.31 1.50 0.21
Syn 0 0.00 1.08 0.08 0.00 1.00
T-Mis 0 0.00 1.92 0.15 0.00 1.00
D-Mis 2 0.15 0.53 0.04 3.76 0.10
LOF 3 0.23 0.36 0.03 8.25 6.1 × 10−3
In-frame indels 1 0.08 0.09 0.01 11.73 0.08
Damaging 6 0.46 0.98 0.08 6.12 5.4 × 10−4
Controls = 1,789
All genes
Total 514 0.29 537.85 0.30 0.96 0.85
Syn 127 0.07 145.35 0.08 0.87 0.94
T-Mis 275 0.15 258.58 0.14 1.06 0.16
D-Mis 64 0.04 72.62 0.04 0.88 0.86
LOF 38 0.02 49.66 0.03 0.77 0.96
In-frame indels 10 0.01 11.64 0.01 0.86 0.73
Damaging 112 0.06 133.92 0.07 0.84 0.98
LOF-intolerant genes (pLI greater than or equal to 0.9)
Total 514 0.29 537.85 0.30 0.96 0.85
Syn 127 0.07 145.35 0.08 0.87 0.94
T-Mis 275 0.15 258.58 0.14 1.06 0.16
D-Mis 64 0.04 72.62 0.04 0.88 0.86
LOF 38 0.02 49.66 0.03 0.77 0.96
In-frame indels 10 0.01 11.64 0.01 0.86 0.73
Damaging 112 0.06 133.92 0.07 0.84 0.98
LOF denotes premature termination, frameshift, or splice site mutation. Damaging includes LOF, D-Mis, and in-frame indels. P values
represent the upper tail of the Poisson probability density function. Because the mutation in GPC4was de novo in the proband’s mother, a
total of 13 offspring were considered in the de novo mutation analysis for cases. D-Mis, damaging missense called by MetaSVM; N, number
of de novo mutations; rate, number of de novo mutations per subject; Syn, synonymous; T-mis, tolerated missense called by MetaSVM.
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TFAP2B is highly intolerant to LOF mutations, with none
identified among >100,000 alleles in ExAC (9) (pLI = 0.99),
making this result all of the more striking (3 LOFs in 12 pro-
bands vs. 0 in 60,706 ExAC controls, P = 6.79 × 10−12).
TFAP2B is a transcription factor involved in neural crest cell
differentiation. Aberrant developmental signaling in cranial neural
crest cells has been demonstrated to cause CS in several mouse
models (10–12). Three probands had metopic synostosis (fusion of
the frontal bones of the skull) with severe trigonocephaly (tri-
angular skull); 2 of these had clinodactyly, and 1 had brachydactyly
(congenital malformations of the fingers) (Fig. 1). The other subject
who had a transmitted LOF mutation in TFAP2B had sagittal
synostosis (fusion of the parietal bones) with severe scaphocephaly
(long, narrow skull) and brachydactyly. A variety of other congenital
abnormalities was seen (SI Appendix, Table S2). In 1 of these
families (SAG249), the mutation-transmitting parent showed no
signs of CS; however, in the second family (MET117), clinical ex-
amination of the transmitting father as well as analysis of his
childhood photographs suggested uncorrected metopic synostosis.
Interestingly, heterozygous damaging mutations in TFAP2B
have previously been implicated in Char syndrome, a syndromic
form of patent ductus arteriosus often presenting with charac-
teristic facies and limb anomalies (13). Notably, several patients
with Char syndrome had abnormal head shapes and ridging over
the cranial sutures, suggesting the possibility of CS (14), although
this was not confirmed. In our patients with TFAP2B mutation,
aside from clear demonstration of CS, several recurrent pheno-
types not previously reported in Char syndrome were observed,
including recurrent pulmonary and otolaryngeal infections (n =
2), hypovitaminosis D (n = 2), and severe growth and develop-
mental delays (n = 2); additional traits observed in single pro-
bands not previously described were severe allergic rhinitis and
asthma (n = 1), recurrent transaminitis, agenesis of the corpus
callosum, seizures, and sensory processing disorder (SI Appendix,
Table S2). Of the 3 probands in whom an echocardiogram was
obtained, only 1 proband, who was asymptomatic, had a patent
ductus arteriosus (PDA), which was monitored and resolved
spontaneously by the age of 7. The phenotypes in these patients
with TFAP2B mutations thus expand the range of phenotypes
resulting from haploinsufficiency, highlighting the pleiotropy and
variable expressivity resulting from these mutations.
We searched for rare (ExAC frequency < 2 × 10−5) and
damaging (LOF or MetaSVM-D missense) variants in TFAP2B
in 485 previously sequenced probands with nonsyndromic sagit-
tal or metopic CS (2, 3). This identified a single TFAP2B dam-
aging missense mutation (p.Q8E, which has MAF = 0 in ExAC)
transmitted from an unaffected parent. This proband had no
extracranial anomalies, and the significance of this damaging
missense variant in a nonsyndromic proband is uncertain. LOF
and damaging missense mutations in TFAP2B thus seem to be
highly enriched in syndromic CS probands in comparison with
nonsyndromic probands.
De Novo Damaging Mutations Enriched in Known Disease Genes and
High pLI Genes. Among the 8 remaining probands, we found de
novo LOF or likely damaging mutations in 5 kindreds. Four of
these mutations were in known Mendelian genes listed in Online
Mendelian Inheritance in Man (OMIM; https://www.omim.org/)
(Poisson P = 7.8 × 10−4; 9.98-fold enrichment) (SI Appendix,
Table S3). Four of these genes had pLI > 0.90, which was not
expected by chance (Poisson P = 5.2 × 10−3; 5.89-fold enrich-
ment), while 1 had pLI = 0.34. Only 1 of these genes had any
prior association with CS. Importantly, however, 3 of these genes
lie in pathways frequently mutated in other syndromic forms of
CS (BMP, Wnt, Ras/ERK, ephrin, hedgehog, STAT, and retinoic
acid pathways as noted previously [1–3]). GLI2, SOX11, and
GPC4 lie in the hedgehog, BMP, and Wnt signaling pathways,
respectively. Among these 8 kindreds, the probability of finding 3
damaging de novo mutations among the 963 genes of the BMP,
Wnt, Ras/ERK, ephrin, hedgehog, STAT, and retinoic acid path-
ways (per gene ontology) by chance is 3.3 × 10−4 (enrichment 23-
fold) (3). This result provides strong support for these mutations
contributing to the pathogenesis of CS in these kindreds.
One proband had a de novo LOF mutation in KAT6A. The
proband was born with combined sagittal and metopic synostosis
Table 2. Likely pathogenic variants in probands with syndromic CS
Kindred identification Type of CS Gene Impact Inheritance ExAC frequency pLI
SAG249 Sagittal TFAP2B M1I (start loss) Inherited (unaffected parent) 0 0.99
MET268 Metopic TFAP2B K276R De novo 0 0.99
MET271 Metopic TFAP2B IVS3+2 T > A De novo 0 0.99
MET117 Metopic TFAP2B R382X Inherited (affected parent) 0 0.99
SAG250 Sagittal and etopic KAT6A E1221X De novo 0 1
LAM108 Lambdoid SOX11 R64H De novo 0 0.34
PSAG38 Sagittal GLI2 A551T De novo 0 1
MET188 Metopic GPC4 V152fs De novo in mother 0 0.95
SAG359 Sagittal CTNNA1 V374_375insSWKMK De novo 0 0.97
Fig. 1. Probands with de novo damaging mutations in TFAP2B. Hands and faces
of the 2 probands as well as pedigrees from each kindred are demonstrated in
each column. Patients were diagnosedwith severe trigonocephaly in early infancy,
with neonatal diagnoses of brachydactyly (MET271) or clinodactyly (MET268).
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and had the de novo mutation p.E1221X. KAT6A encodes a
histone acetyltransferase implicated in H3K9 and H3K18 acet-
ylation and has a pLI of 1.0. De novo LOF mutations in this gene
were previously reported in probands with complex syndromic
intellectual disability and developmental delay (15, 16); 3 sub-
jects from 1 study were reported to have midline CS (16). Many
additional syndromic findings in our proband overlapped with
findings in other reported KAT6A-mutant patients, including a
patent ductus arteriosus, an atrial septal defect and patent foramen
ovale, dysplastic mitral valve with mitral and tricuspid valve re-
gurgitation, hypotonia, down-turned corners of the mouth, micro-
genia, an inverted nipple, bilateral clinodactyly of both fifth toes and
mild 2- to 3-toe syndactyly, hemangiomas (n = 10) widely distributed
across the body surface, oral feeding difficulties with nasogastric
tube dependency, laryngomalacia, seizures, hypoplastic corpus cal-
losum with white matter atrophy, bilateral cryptorchidism, and an
underdeveloped scrotum (SI Appendix, Table S2). In addition, this
child had several features not previously described, including bron-
chial atrophy involving the right mainstem and upper lobe bronchus,
cupped and posteriorly rotated ears bilaterally, and the absence
of tooth eruption at age 2. The extensive overlap of findings with
other previously described cases leaves little doubt that the identi-
fied mutation is causally related to the phenotypes in this patient
and provides evidence of additional expansion of the phenotypes
resulting from haploinsufficiency for KAT6A. Consistent with this
notion, no other de novo damaging mutations or LOF mutations
in OMIM or high pLI genes were found in this proband.
A de novo mutation at a highly conserved residue in a highly
conserved segment of GLI2 (p.A551T) was identified in a child
born with sagittal CS, neurogenic bladder, cerebral palsy, atro-
phy of the right optic nerve, hydrocephalus, absence of the right
thumb, severe kyphosis, and scoliosis (Fig. 2 and SI Appendix,
Table S2). No other likely de novo mutations were identified in
this proband, and there were no transmitted damaging genotypes
in high pLI genes or known OMIM genes identified in this
proband. GLI2 encodes a zinc finger transcription factor in the
hedgehog signaling pathway and is highly intolerant to LOF
mutation (pLI = 1.0). The identified variant lies within the fourth
C2H2 zinc finger domain; the fourth and fifth zinc fingers mediate
the binding of GLI2 to its cognate DNA sequence (17). The
crystal structure of the close paralog encoded by GLI1, bound to
its cognate DNA sequence, has been determined (Protein Data
Bank [PDB] ID code 2GLI) (18). These proteins are highly
homologous, including 92% sequence identity across the fourth
zinc finger, with 100% identity across the 21-amino acid segment
that contains the sequences that directly interact with DNA ba-
ses (amino acids 547 to 552) (SI Appendix, Fig. S1). Residue
A551 is expected to lie in the center of the “Finger 4”motif, which
recognizes the major groove; this alanine is predicted to abut the
adjacent nucleotide (Fig. 2G). Substitution of the larger and hy-
drophilic threonine mutation is highly likely to deleteriously im-
pact, or alter, the binding of GLI2 to DNA.
GLI2 is a key mediator of hedgehog signaling, a pathway that
has been implicated in cranial suture morphogenesis, brain de-
velopment, and skeletal patterning (19). GLI2 haploinsufficiency
has previously been implicated in a spectrum of phenotypes,
including postaxial polydactyly, structural brain abnormalities,
hypopituitarism, unusual facial features, delayed growth, facial
clefts, and holoprosencephaly (20, 21). The phenotypes of our
proband are mostly distinct from those seen in patients with LOF
mutations in GLI2, although this patient’s neurogeneic bladder
is consistent with the urogenital anomalies observed in GLI2
knockout mice (22). The altered binding interaction with DNA
raises the possibility that this mutation has complex effects entail-
ing both LOF and neomorphic effects resulting from binding to
ectopic DNA sequences; this could account for the distinctive
phenotypic features of this patient.
There was a damaging de novo variant in SOX11 (p.R64H) in
a child with unilateral lambdoid synostosis, microgenia, hip
dysplasia, lower lip eversion, low-set ears, developmental delay, hy-
potonia, aplasia of the fifth distal phalanx bilaterally, postaxial
polydactyly, and clinodactyly (Fig. 3A and SI Appendix, Table S2).
SOX11 is a transcription factor downstream of BMP signaling
previously demonstrated to enhance early osteoblast differentiation
by increasing expression of lineage-specific transcription factors
RUNX2 and SP7 (23); SOX11 has a pLI of 0.34. SOX11 is also
involved in the embryonic neurogenesis and tissue modeling during
development. LOF mutations in SOX11 have previously been im-
plicated in syndromic intellectual disability resembling Coffin–Siris
syndrome, which usually presents with hypotonia, microcephaly, and
coarse facial features in addition to severe developmental delay (24).
There is very high sequence identity over 90% between
SOX11 and the C-group Sox protein SOX4 (SI Appendix, Fig.
S1), strongly suggesting that SOX4 and SOX11 fold and bind
DNA in a similar manner. Analysis of sequence alignment and
the crystal structure of SOX4 bound to DNA (PDB ID code 3U2B)
(25) (Fig. 3C) indicate that Arg64 should function similarly to
the equivalent conserved arginine in SOX4 and SOX17 as a critical
residue for DNA sequence recognition (25). Mutation of Arg64 to
histidine is, therefore, predicted to significantly impair correct
DNA recognition. To our knowledge, the presence of lambdoid CS,
postaxial polydactyly, and hip dysplasia has not been reported in
association with SOX11 mutation. While there is overlap of the
features of this patient with prior patients with haploinsufficiency
for SOX11, the previously unreported features seen in our patient
raise the question of whether there might be neomorphic effects of
altering the DNA binding specificity of SOX11.
We identified a de novo 15-nucleotide in-frame insertion
(p.V374_375insSWKMK) in CTNNA1, which encodes an α-catenin
protein; α-catenin proteins link the cytoplasmic domain of cadherins
to filamentous actins and help stabilize adherens junctions by
binding to both filamentous actin and vinculin. They are intricately
involved in multiple complexes that regulate cell adhesion and
differentiation. The proband was born with polydactyly of the right
thumb, a right supernumerary nipple, 3 cartilaginous skin tags
Fig. 2. De novo mutation in GLI2. (A) The proband at 8 y of age, demon-
strating bitemporal narrowing as a result of uncorrected sagittal synostosis.
(B) T2-weighted MRI demonstrating hydrocephalus, white matter abnor-
malities, and hypoplasia of the corpus callosum. The patient was also born
with right thumb agenesis (C) and severe kyphosis and scoliosis (D and E).
Hip dysplasia requiring operative management is also evident at the bottom
of D. (F) The mutation p.A551T in GLI2 was only present in the proband but
not in parents. (G) The crystal structure of the paralog GLI1 (18) (PDB ID code
2GLI) is shown, indicating the location of A551 within the major grove-
binding Finger 4 motif and abutting the adjacent nucleotide. Structural
figures were generated using Pymol (https://pymol.org/2/).
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around his right ear, tooth enamel defects, a hydrocele, an inguinal
hernia, and sagittal CS (SI Appendix, Table S2). CTNNA1 has a pLI
of 0.97. The structural basis of autoregulation for α-catenin
interaction with vinculin is thought to be mediated by a major
conformational change in the vinculin-binding domain (26); the
autoinhibited crystal structure of α-catenin shows this domain to be
a 4-helix bundle (27), but in its complex with vinculin, this domain
is “unfurled” (26). The p.V374_375insSWKMK insert is located in
the center of 1 of the α-helices of the vinculin-binding domain (SI
Appendix, Fig. S2). The insertion is expected to destabilize the helix
and consequently, the autoinhibited 4-helix bundle, perhaps
resulting in either altered vinculin binding or α-catenin degradation.
Lastly, we identified a hemizygous LOF mutation in GPC4
(p.V152fs*3), a regulator of Wnt signaling, in a male child with
syndromic metopic synostosis (Fig. 4A). This mutation was de
novo in the proband’s mother. GPC4 has a pLI of 0.95 (Fig. 4B).
The proband also had severe growth delay with shortened long
bones, a single cupped ear, depressed nasal bridge, short nose,
amblyopia, nystagmus, and gingival hyperplasia (Fig. 4A and SI
Appendix, Table S2). A proband without CS yet with similar extra-
cranial anomalies resembling Robinow syndrome was recently
reported in a child with a hemizygous GPC4 variant (28). The
findings in our proband lend strong support to the existence of
an X-linked form of Robinow syndrome occurring via GPC4 in-
sufficiency. They also lend additional support to the link between
cranial suture morphogenesis and regulation ofWnt signaling (3, 29).
We recently described an association between rare, damaging
variants in SMAD6 and midline CS, with penetrance of disease
modified by a common risk allele (rs1884302) downstream of
BMP2 (2). We genotyped rs1884302 in these kindreds with
syndromic CS and found no significant association between the
risk allele and disease (P = 0.25, binomial test; “C” risk allele
transmitted in 5 of 9 possible heterozygous transmissions). The
BMP2 risk allele was present in a heterozygous (n = 2) or ho-
mozygous (n = 1) state in 3 of 4 probands with syndromic sagittal
CS, consistent with an association of this allele to sagittal CS (30).
Discussion
We have found rare damaging mutations in genes that are highly
intolerant to LOF in 8 of 12 probands with syndromic CS who
had previously negative genetic studies. Four of these mutations
were in TFAP2B, strongly implicating this gene in syndromic CS.
Mutations in TFAP2B had previously been implicated in patent
ductus arteriosus with limb anomalies, features that were
variable among our TFAP2B-mutant probands with CS. This
finding clearly establishes TFAP2B as a syndromic CS gene and
underscores the pleiotropy and variable expressivity resulting
from haploinsufficiency for this gene.
Among the remaining 8 probands, 5 had de novo damaging
mutations, all but 1 in very high pLI genes. Haploinsufficiency
for only 1, KAT6A, had previously shown any association with
CS. Haploinsufficiency for 3 others, GLI2, SOX11, and GPC4,
has been associated with other congenital malformations and
acts in the Wnt, BMP, and hedgehog signaling pathways in which
mutation in other genes has been frequently implicated in syn-
dromic CS. These findings are highly unlikely to have occurred
by chance and strongly suggest that the identified mutations are
causal to CS in these patients. The significance of mutation in 2 of
these genes is further supported by phenotypic overlap of patients
harboring these mutations with other patients with mutation in the
same genes (GPC4 and SOX11). Lastly, we identified a damaging
de novo in-frame insertion within the vinculin-binding domain of
CTNNA1, potentially implicating another pathway regulating cell
differentiation in CS. It would be of interest to determine whether
other patients previously shown to have haploinsufficient mutations
in these genes have previously unrecognized CS. Additionally,
however, 2 of these genes encode transcription factors and had
mutations at positions in immediate proximity to sites of interaction
with cognate DNA binding sites, raising the possibility that these
mutations might impart more complex effects than simple LOF.
Our study of just 12 syndromic CS patients with negative genetic
studies for mutations in known CS genes identified 1 statistically
significant CS gene (TFAP2B), provided confirmation for others
(KAT6A and GPC4), and provided support for the role of 3 oth-
ers. These findings make clear that additional genes remain to be
identified among “mutation-negative” subjects, providing strong
motivation to study all such patients. The 3 remaining patients
who do not have putative causal mutations are candidates for
additional study. Small copy number variants, deep intronic
splice mutations, oligogenic inheritance, and environmental
phenocopies are all potential explanations. Nevertheless, the
high diagnostic rate of these mutation-negative kindreds strongly
supports exome sequencing of case-parent trios as the appro-
priate next step in management for syndromic CS probands
without mutations at prevalent syndromic loci (31).
The results also provide continuing evidence (3, 5, 6, 32) of
pleiotropy and variable expressivity resulting from mutation in
genes in which haploinsufficiency causes disease, with observed
Fig. 3. De novo mutation in SOX11. (A) Note the
full cheeks, everted lower lip, brachydactyly, and
clinodactyly (37). Three-dimensional computed to-
mography reconstruction demonstrates R lambdoid
CS. The X-ray of the hand demonstrates absence of
the fifth digit distal phalanx. The proband’s sixth
digit was removed early in infancy and thus, is
not shown. (B) The mutation p.R64H in SOX11
was present in the proband but not in parents.
(C ) Analysis of sequence alignment indicates that
Arg64 should function similar to the equivalent
conserved arginine in SOX4 and SOX17 as a crit-
ical residue for DNA sequence recognition (25). Structural analysis of the nearly identical Sox4 in complex with DNA (PDB ID code 3U2B) (25) in-
dicates that arginine at the location of R64 is critical for proper DNA sequence recognition.
Fig. 4. Proband with hemizygous GPC4 LOF mutation. (A) The images
demonstrate trigonocephaly, a depressed nasal bridge, and a cupped right
ear. (B) Pedigree of family with GPC4 LOF mutation: + represents a wild-type
allele, and D represents the mutant allele of GPC4, p.V152fs. The frameshift
mutation was de novo in the affected child’s mother as denoted by the star.
This mutation was transmitted to her son, who was hemizygous for the GPC4
LOF mutation. Sanger sequencing traces are shown in SI Appendix, Fig. S3.
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phenotypes showing incomplete overlap with phenotypes previously
associated with damaging mutations in these genes. For example,
analysis of 22 individuals from a large kindred harboring the same
LOF mutation in TFAP2B demonstrated ∼50% penetrance of
PDA and 80% penetrance of facial dysmorphology but nearly
complete penetrance of clinodactyly; thus, even in the same genetic
background, considerable variable expressivity has been observed
(14). The findings underscore the role of ascertainment in the
phenotypes observed. The striking phenotypic variability could be
explained by the effects of variants at other loci, allelic effects,
environmental effects, or chance. In nonsyndromic CS, we recently
demonstrated the clear role of nonadditive interactions of rare
SMAD6 LOF mutations and a common variant near BMP2, with
penetrance of CS drastically increasing with the combination of
these risk loci over the presence of either alone (2). Interestingly,
haploinsufficiency for SMAD6 has also been implicated in con-
genital heart disease (CHD) (6); none of these patients have had
concurrent CS. Thus, it is plausible that the combination of rare
alleles with common modifiers at other loci might underlie the
phenotypic variability observed in these and other Mendelian dis-
orders. Significant overlap was also recently shown to exist between
genes harboring rare mutation with large effect in CHD and autism
(6), which might also be explained by modifier loci. These results
also comport with findings in CHD in which de novo mutations
contribute to ∼3% of probands with isolated CHD but 27% of
CHD with complex extracardiac phenotypes (32), emphasizing the
high yield for rare mutations with large effect in syndromic patients.
Large-scale exome sequencing projects have been highly suc-
cessful in identifying genes and pathways implicated in diseases
featuring high locus heterogeneity in recent years, including
autism (33–36), CHD (6, 7, 32), and CS (2, 3). The identification
of a high frequency of damaging mutations in genes highly in-
tolerant to LOF in this small cohort implies that sequencing a
substantially larger cohort of mutation-negative syndromic trios
will be highly productive in identifying additional loci affecting
craniofacial development. We anticipate that similar findings will
apply to many other syndromic traits.
Methods
Subjects and Samples. Participants for this study were ascertained from the
Yale Pediatric Craniofacial Clinic; from the Pediatric Neurosurgery Clinic at
the Medical University of Silesia, Poland; or by responding to an invitation
posted on the Cranio Kids–Craniosynostosis Support and Craniosynostosis–
Positional Plagiocephaly Support Facebook pages. All participating individ-
uals or their parents provided written informed consent to participate in a
study of the genetic cause of CS in their family. Inclusion criteria included a
diagnosis of syndromic CS in the absence of known syndromic forms of
disease by a craniofacial plastic surgeon or pediatric neurosurgeon. The
study protocol was approved by the Yale Human Investigation Committee
Institutional Review Board. Patient photographs were used with family
permission and were provided by participating families or treating clinicians.
Exome Sequencing and Analysis.DNAwas prepared from buccal swab or saliva
samples according to the manufacturer’s protocol. Exome sequencing was
performed by exon capture using the IDT xGen capture reagent followed by
99 base paired end sequencing on the Illumina HiSeq 2000, with variant calls
analyzed as previously described (3).
Burden of De Novo Mutations. Statistical analysis of the probability of ob-
serving multiple damaging de novo mutations in an individual gene in CS
cases was performed in R using the denovolyzeR package as previously de-
scribed (2, 37). The expected number of de novo mutations in each gene
across variant classes was calculated, and this value was compared with the
observed number using Poisson statistics (8).
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